Tepezza Injection, Powder, Lyophilized, For Solution
Product Images NDC 75987-130

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Tepezza (NDC 75987-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Horizon Therapeutics Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tepezza 01)

This is a table showing the change in proptosis (bulging of the eye) from baseline to weeks 12, 18, and 24 for two groups of individuals: a placebo group (N=42) and a TEPEZZA group (N=41). There is no other information available in the text.*

FDA Label Image

Principal Display Panel (500 mg Vial Carton)

TEPEZZA is an injection for intravenous infusion only that contains teprotumumab-trbw. It is supplied as a single-dose vial, which should be discarded if any portion remains unused. The vial packaging is designed to protect its contents from light. Unopened vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F), and freezing should be avoided. TEPEZZA has no U.S. standard of potency. The enclosed package insert provides complete information on dosage and administration, including instructions for reconstitution. It is manufactured by Horizon Therapeutics in Denmark and distributed by Horizon Therapeutics USA, Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.